These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24032532)

  • 1. Research progress on the mechanisms of combined bevacizumab and radiotherapy.
    Zhuang HQ; Yuan ZY; Wang P
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):129-34. PubMed ID: 24032532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of angiogenesis inhibitors combined with radiation therapy.
    Nieder C; Wiedenmann N; Andratschke N; Molls M
    Cancer Treat Rev; 2006 Aug; 32(5):348-64. PubMed ID: 16713103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience.
    Nieder C; Wiedenmann N; Andratschke NH; Astner ST; Molls M
    Rev Recent Clin Trials; 2007 Sep; 2(3):163-8. PubMed ID: 18474001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of clinical trials of radiation combined with antiangiogenic therapy.
    Senan S; Smit EF
    Oncologist; 2007 Apr; 12(4):465-77. PubMed ID: 17470689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
    Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
    Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain.
    Dashti SR; Spalding A; Kadner RJ; Yao T; Kumar A; Sun DA; LaRocca R
    J Neurosurg Pediatr; 2015 Jan; 15(1):20-5. PubMed ID: 25360851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taming vessels to treat cancer.
    Jain RK
    Sci Am; 2008 Jan; 298(1):56-63. PubMed ID: 18225696
    [No Abstract]   [Full Text] [Related]  

  • 13. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.
    Dings RP; Loren M; Heun H; McNiel E; Griffioen AW; Mayo KH; Griffin RJ
    Clin Cancer Res; 2007 Jun; 13(11):3395-402. PubMed ID: 17545548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
    Sudaka A; Susini A; Lo Nigro C; Fischel JL; Toussan N; Formento P; Tonissi F; Lattanzio L; Russi E; Etienne-Grimaldi MC; Merlano M; Milano G
    Invest New Drugs; 2013 Feb; 31(1):59-65. PubMed ID: 22714791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing the potential of bevacizumab in cancer treatment.
    Bergsland E; Dickler MN
    Oncologist; 2004; 9 Suppl 1():36-42. PubMed ID: 15178814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
    Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
    Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
    Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
    Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.
    Bellati F; Napoletano C; Gasparri ML; Ruscito I; Marchetti C; Pignata S; Tomao F; Benedetti Panici P; Nuti M
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):35-46. PubMed ID: 22056314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.